SUMMARY Using an antiserum raised against tumour angiogenesis factor (TAF) we have developed a radioimmunoassay for retina and tumour angiogenesis factor(s). This antiserum was previously shown to bind to both human and animal tumour extracts and to inhibit the angiogenesis induced by TAF in vivo. TAF from rat Walker tumour was used for iodination by the chloramine-T method. An excess of '25I-labelled TAF was incubated with TAF antibody in the absence (maximum binding) and presence (inhibition of maximum binding) of unlabelled tissue extract. A double antibody technique was used to separate free and bound TAF. Unlabelled human Wilms tumour TAF was used as a standard. The extent of inhibition of '25I-TAF-anti-TAF binding provided a measure of TAF in tissue extracts examined. Extracts of normal bovine retina, cornea, lung, aorta, lymph nodes, iris, vitreous humour, and human tumours and normal human pituitary and liver were assayed. Only bovine retina and human tumours were found to contain angiogenesis factor. These findings, together with our earlier results, suggest that angiogenesis factor from both bovine retina and human tumours induce angiogenesis in vivo and possess common antigenic determinants. The presence of angiogenesis factor in healthy retina and its relationship to neovascularisation in clinical conditions is discussed.
Over a decade ago Folkman and his associates demonstrated angiogenesis activity in semipurified extracts of solid tumours.' A number of other investigators have also found such an activity in nontumour sources, particularly retina.2" For instance, Federman et al. reported the growth of limbal vessels in response to retinal tissue implants in rabbit cornea. 5 More recently extracts of retinal tissues of many species have been shown to contain angiogenesis factor.3^We have also purified an angiogenesis factor from healthy feline3 and bovine retinas (unpublished data) which appears to be similar to those isolated previously by us from tumours and synovial fluid of patients with joint disease.2 However, the interrelationship and differences between various angiogenesis factors remain unknown. In an earlier report we described the development of 2 immunoassays, radioimmunoassay (RIA) and radioimmunometric assay (RIMA), to quantitate angiogenesis factor in tumour extracts.'0
In this communication we have used RIA to quantitate angiogenesis factor in bovine retina and tumour extracts.
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Materials and methods
RIA buffer. 0-1 M phosphate buffer (pH 7-6) containing 0f15 M NaCl, 0-05% sodium azide and 0-5% bovine serum albumin (Sigma Fraction V Powder).
Tumour angiogenesis factor (TAF). TAF was extracted from rat Walker and human Wilms tumours according to the method described by Phillips and Kumar" and stored lyophilised at 4°C. The angiogenic substance, although only partially pure, will be referred to as tumour angiogenesis factor (TAF). The TAF was tested by a chorioallantoic membrane (CAM) assay. " Fig. 1 shows a control CAM and 2 other CAMs treated with bovine retina angiogenesis factor and tumour angiogenesis factor. Both tumours and retina angiogenesis factors induced similar stimulation as shown by the spoke-wheel convergence of blood vessels towards the site of TAF application.
Bovine tissue extracts. For each extraction 20 bovine retinas (approximately 10 g) were collected from the local abattoir and transported to the laboratory in crushed ice. The extraction procedure involved homogenisation of the tissue in RIA buffer 286 (1 g/5 ml) for 3 minutes with a Silverson sealed unit homogeniser. The homogenate was further ultrasonicated for 1 minute (2 bursts each lasting 20 seconds). 150 ,ul of 40% TCA solution was added to the controls instead of the anti-rabbit precipitating serum. The tubes were incubated overnight at 4°C, followed by centrifugation at 2000 g for 30 min at 4°C. The supernatant was discarded and the radioactivity in the residues was measured in a gamma counter.
Results
Gel filtration of different batches of '251-labelled Walker TAF produced 3 or 4 peaks. The percentage of 125I protein (TCA precipitable) varied between 94% in the first to about 4% in the fourth batch. Peak 1 was found to bind to TAF antiserum. In a few instances peak 2 also bound to antiserum. In such human tumour extracts (Fig. 4) . This indicated an immunological identity between Wilms TAF and the extracts of bovine retina and human tumours.
The quantity of angiogenesis factor in a tissue extract producing an inhibition of the maximum binding was expressed as the quantity of Wilms TAF producing similar inhibition. The values for angiogenesis factor were expressed as both ,ug TAF/g wet weight and ,g TAF/,ug protein of the tissue (Fig. 5 and Table 1 ). The level of angiogenesis factor in retinal extracts varied from 378 to 2640 ,ug TAF/g wet weight. Extracts ofother normal bovine tissues did not inhibit the binding to any significant extent, that is, the angiogenesis factor if present in these tissues could not be detected by the present RIA. Considerable inhibition was produced by all human tumour extracts but not by either normal human pituitary or liver. The values for different tumour types varied from 48 to 2025 ,ug TAF/g wet weight.
The detection limits (defined as the amount of protein producing 25% inhibition of the maximum binding) of the assay are shown in Table 2 . 9 5-370 ,ug protein of the retinal extracts and 45-170 ug protein of the human tumour extracts were required to produce 25% inhibition.
Discussion
We have developed a radioimmunoassay (RIA) for an angiogenesis factor from bovine retina using an antiserum raised against rat Walker TAF. This antiserum has been previously reported to bind to human and animal tumours (detected by gel diffusion and immunofluorescence) and to inhibit TAF induced angiogenesis in vivo." Our data show that TAF and the extracts of bovine retina and human tumours possess common antigenic determinant(s), which are either absent or present only in much smaller concentrations in normal human pituitary and liver and bovine aorta, lung, cornea, iris, lymph node, and vitreous humour. The inhibition curves produced by retinal and tumour extracts were parallel to those produced by Wilms TAF. The amounts of angiogenesis factor, estimated as equivalent of Wilms TAF, were equal or slightly more in bovine retinal extracts compared with tumour extracts. These findings confirm and significantly extend our previous work.3 Partially and highly purified extracts from tumours and healthy feline3 and bovine retinas (unpublished data) were found to give an angiogenic response on the chick chorioallantoic membrane. These extracts also bound to TAF antiserum linked to a sepharose affinity column. Furthermore, D'Amore et al. have also isolated an angiogenesis factor from normal bovine retina.9 The structural identity of tumour or retinal angiogenesis factor(s) is not known.
For a solid tumour to grow beyond a size of a few cubic mm it needs the formation of new blood vessels, and thus the role of angiogenesis factor in tumours is obvious. Why a large amount of angiogenesis factor is present in normal retina and why its presence does not induce angiogenesis requires an explanatioñ 
